PA-BENTLEY-SYSTEMS
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, announced today, following the initial public offering of its stock on September 23, the company’s successful recruitment for three significant operating positions. All three new executives are presently in place.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005179/en/
Greg Bentley said, “While Bentley Systems accomplished much throughout our 36 years of growth as a privately-held company, and I am proud of our executive talent depth, we obviously could not internally develop public company experience. The principal purpose of our IPO last month was to assure market liquidity for our colleagues, and especially executive shareholders, in advance of many anticipated retirements. In turn, for the executive opportunities accordingly created, our new higher profile as a public company serves to help attract world-class talent from top public technology companies.
“I enthusiastically welcome Nicholas Cumins, Kat Lord-Levins, and Chris Bradshaw to share their energy, wisdom, and especially their lessons learned within public companies. And on his retirement after 26 years, I particularly thank and congratulate Bhupinder Singh, truly a 'foundation pillar' of Bentley Systems!”
Chief Product Officer: Nicholas Cumins
Nicholas Cumins (based in Munich, Germany) reports to Greg Bentley, CEO. He succeeds Bhupinder Singh, who has retired.
Nicholas leads the product organization, responsible for the definition, development, and adoption of Bentley’s software solutions for advancing infrastructure. He has over 20 years of product leadership experience with established and startup companies in multiple software industries. Prior to joining Bentley, Nicholas served as general manager of SAP Marketing Cloud, a comprehensive marketing automation platform. He also served as chief product officer of Scytl, a platform for online voting, in Barcelona, and senior vice president of product with OpenX, a pioneer in programmatic advertising, in Los Angeles. Before OpenX, Nicholas had already served in a variety of senior roles at SAP, including product management, corporate strategy, and business development in the United States, Germany, and France. He earned master’s degrees in law and in business from Paris II Panthéon-Assas University.
Image: Nicholas Cumins
Chief Success Officer: Katriona Lord-Levins
Katriona Lord-Levins (based in San Francisco, CA) reports to Greg Bentley, CEO. The Chief Success Officer is a new position.
Kat is responsible for leading the user and enterprise success teams, which focus on helping users realize their business goals with Bentley technologies. By ensuring Bentley has established processes to deliver proven outcomes and listen to user needs, Kat works to make Bentley the solution of choice and create loyal users. Before joining Bentley, Kat worked for two decades at Autodesk in a variety of roles, the most recent of which focused on building and leading the construction business unit customer success team. Prior to Autodesk she worked at Alias Research in Toronto, a software company that produced high-end 3D graphics software. Kat studied computer science at the University of Toronto.
Image: Katriona Lord-Levins
Chief Marketing Officer: Chris Bradshaw
Chris Bradshaw (based in Exton, PA) reports to Gus Bergsma, Chief Revenue Officer. He succeeds Carey Mann, who after 28 years becomes BSY’s inaugural Investor Relations Officer.
Chris was previously chief marketing and product officer of Blue Prism Group, a London-based software company that specializes in robotic process automation. There, Chris was responsible for vision, strategy, and road maps for the entire software portfolio. From 1991 until 2017, Chris served at Autodesk in a variety of leadership roles, including chief marketing officer, and created the Infrastructure Solutions Division. Earlier, he managed flight software development for the United States Air Force, where he guided the development, testing, and integration of on-board computer systems for two national space programs. Chris currently serves on the board of directors of Project Lead the Way, a non-profit that provides STEM education programs to K-12 students in the United States. He earned a bachelor’s degree in electrical engineering from Cornell University, and an M.B.A. from Duke University.
Image: Chris Bradshaw
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, and industrial facilities. Our offerings include MicroStation -based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $700 million, in 172 countries. www.bentley.com
© 2020 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, iTwin, MicroStation, and ProjectWise are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005179/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom